Table 3.
Comparison of pooled PCR-uncorrected proportions of adequate clinical and parasitological response between AQ-SP and ACT.
| ACT | Odds-ratio (95% CI), as compared to AQ-SP | |||
|---|---|---|---|---|
| day 2 | day 3 | day 14 | day 28 | |
| AM-LM | 25.6 (8.21-79.5)* |
ND | 2.81 (0.28-27.7) |
6.32 (1.35-29.6)* |
| AS-AQ | 26.4 (12.4-56.4)* |
16.0 (3.35-76.1)* |
0.72 (0.20-2.62) |
0.80 (0.40-1.61) |
| AS-CD | 34.7 (11.2-107)* |
ND | 0.26 (0.07-0.96)* |
0.35 (0.16-0.75)* |
| AS-MQ | 11.4 (4.76-27.1)* |
3.26 (0.84-12.7) |
0.36 (0.10-1.41) |
1.45 (0.57-3.71) |
| AS-SP | 18.9 (8.64-41.2)* |
5.30 (1.57-17.9)* |
0.91 (0.22-3.64) |
1.34 (0.60-2.93) |
| DH-PP | 37.4 (12.2-115)* |
ND | 0.80 (0.18-3.50) |
9.16 (2.0-42.5)* |
Patients who were excluded or lost-to-follow-up were not included in the analysis. Data from a total of 709 patients were analysed, with treatment as a single covariate. Asterisks denote P < 0.05. ND (not done) denotes infinite OR due to 100% ACPR. On day 7, 100% ACPR was observed with all bitherapies. ACT, artemisinin-based combination therapies; AS-AQ, artesunate-amodiaquine; AS-MQ, artesunate-mefloquine; AS-SP, artesunate-sulphadoxine-pyrimethamine; AM-LM, artemether-lumefantrine; AS-CD, artesunate-chlorproguanil-dapsone; DH-PP, dihydroartemisinin-piperaquine; AQ-SP, amodiaquine-sulphadoxine-pyrimethamine.